Although presenting features and early sequelae of non-ST-segment elevation acute coronary syndromes (NSTE-ACS) are well described, less is known about longer-term risks and modes of death. The purpose of this study was to characterize modes of death following NSTE-ACS in clinical trial populations. 
Introduction
Non-ST-segment elevation acute coronary syndromes (NSTE-ACS) now represent a greater proportion of acute coronary syndrome (ACS) events than ST-segment elevation myocardial infarctions (STEMI). 1 This trend may be related to changes in preventive therapies (e.g. greater use of aspirin and statins), behaviours (e.g. lower rates of smoking), 1 and shifting underlying pathophysiology of ACS. 2 Although early sequelae of NSTE-ACS have been well described, less is known about the longer-term risks. For example, the extent to
Methods

Study design and population
The study population was derived from the TIMI Study Group clinical trials. The merged database developed for this analysis included subject level data from TIMI trials enrolling patients with a diagnosis of NSTE-ACS with trial initiation and completion between 1989 and 2014. No distinction was made between non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina (UA), since the advent of more sensitive troponin assays has increasingly led to reclassification of UA as NSTEMI over time. 4 Data from nine trials each contributing <10 deaths and two trials with > _10 deaths but with median follow-up duration <100 days (n = 58 deaths in total) were excluded. In total, 14 trials with > _10 deaths and median follow-up duration > _100 days were included (see Supplementary material online, Appendix S1).
Death classification
For all patients who died, the general class of death was characterized as: cardiovascular (CV), bleeding, or non-CV/non-bleeding. Cardiovascular deaths were further subdivided into specific modes of death, including sudden death (SD), recurrent myocardial infarction (MI), heart failure (including cardiogenic shock), and other CV death (miscellaneous category including ischaemic stroke, pulmonary embolism, acute aortic syndromes, and cardiac rupture). Definitions were adapted from the American College of Cardiology/American Heart Association report on key data elements and definitions for CV endpoint events in clinical trials (see Supplementary material online, Appendix S2). 5 Of note, SD, which is often referred to as sudden cardiac death in other analyses, was defined as death occurring unexpectedly and not following MI. Since this category was not limited to death due to an identified arrhythmia, and included unwitnessed death in a subject seen alive and clinically stable < _24 h before being found dead without any evidence supporting a specific non-CV mode of death, we elected to use the more general term 'sudden death' in this analysis. In 12 of the 14 trials, involving 2427 of the total 3147 deaths, an independent Clinical Events Committee (CEC) classified mode of death using predefined definitions. 5 All adjudicated deaths were reviewed by two of the authors (D.D.B. and R.P.G.) and, as needed, reclassified according to the uniform prespecified definitions applied in this analysis based on the event terms reported on the CEC adjudication forms. For the two trials without a CEC (720 deaths, 23% of the total), death was classified based on review of the case record forms by the same authors (D.D.B. and R.P.G.) using the same uniform definitions.
Data analysis
The cumulative mortality rates of all NSTE-ACS patients in the merged database were calculated by the complement of Kaplan-Meier survival estimates. For initial analyses, the time origin was anchored at the date of randomization for each patient. For estimating risks of each general class and specific CV mode of death, a cumulative incidence function approach was used due to the presence of competing risks. 6 To describe survival experiences beyond 30 days from the onset of the qualifying event (index NSTE-ACS) rather than study enrolment (randomization date), an additional delayed entry analysis was performed, and accounted for competing risks of different modes of death. [7] [8] [9] [10] Mortality rates at 1 year based on Kaplan-Meier estimates were calculated for various baseline patient characteristics. Both the general class and specific mode of death were stratified according to timing of death relative to the date of randomization, with prespecified time intervals of 0-30 days and >30 days. Differences in mode of death between these time intervals were evaluated using the v 2 test.
We performed two subgroup analyses: (i) in patients with vs. without a history of heart failure at the time of trial enrolment and (ii) in patients enrolled in a trial with a start date prior to vs. after 31 December 2000. The relative risk of prior heart failure on overall mortality was calculated using a multivariable Cox model adjusted for differences in baseline characteristics. Two sensitivity analyses were also performed: one restricted to patients enrolled with NSTEMI (i.e. excluding patients with UA), and another restricted to deaths occurring after the index hospitalization to control for potential bias related to in-hospital monitoring, which could have affected mode of death classification in the 0-30-day period. Deaths from two trials (TIMI 51 and TIMI 52, see Table 1 ) were excluded from the second sensitivity analysis because index hospitalization discharge dates were not available. Results are reported in terms of adjusted hazard ratios and 95% confidence intervals (CIs).
Statistical significance was assessed at a nominal alpha level of 0.05. All reported P-values were two-sided. All statistical computations were done with SAS System V9.3 (SAS Institute Inc., Cary, NC, USA) and R software v3.01 (www.r-project.org).
Results
The primary cohort included 66 252 patients enrolled in 14 TIMI trials with a diagnosis of NSTE-ACS ( Table 1) . The median age of the overall population was 63 years and 30% were women ( Table 2) . Thirty percent of patients had a prior MI and 11% had a history of heart failure at the time of trial enrolment. Although exclusion criteria varied across trials, most trials excluded patients with cardiogenic shock, known bleeding diathesis or recent significant bleeding, severe renal dysfunction, or a severe comorbid condition with less than 1-year life expectancy.
The median time from onset of the index event to study enrolment was 1 day [interquartile range (IQR) 1-4 days]. The median follow-up time was 372 days (IQR 218-521 days). There were 3147 (4.8%) deaths through the last known follow-up. Death rates based on Kaplan-Meier estimates were 1.5% at 30 days (95% CI 1.4-1.6%), 3.0% at 6 months (95% CI 2.9-3.2%), 4.3% at 1 year (95% CI 4.2-4.5%), and 6.5% at 2 years (95% CI 6.3-6.8%) (Figure 1) . Older patients and patients with a greater burden of atherosclerotic CV disease (including history of prior MI, history of angina, history of prior stroke, and known peripheral arterial disease) had an increased risk of death at 1 year following NSTE-ACS (each P < 0.001) ( Table 2) .
There was sufficient information available to classify mode of death in 2606 (82.8%) patients. Of these, 1958 (75.1%) died from a CV event, 79 (3.0%) had a fatal bleeding event, and 569 (21.8%) died from a non-CV event other than bleeding ( Table 3) . The crude cumulative incidence of CV death, fatal bleeding, and death from a non-CV/non-bleeding event was 2.69%, 0.11%, and 0.66%, respectively, at 1 year following trial enrolment for NSTE-ACS (Take home figure) .
a landmark analysis starting at 30 days after the qualifying NSTE-ACS event, there were 1703 deaths with known mode of death, and the cumulative incidence of CV death, fatal bleeding, and death from a non-CV/non-bleeding event at 1 year was 1.52%, 0.06%, 0.50%, respectively ( Figure 2A) . The most common modes of the 1958 CV deaths in the primary analysis were SD and recurrent MI, which represented 36.4% (n = 713) and 23 .4% (n = 458) of these deaths, respectively. Heart failure accounted for 19 .1% (n = 374) of CV deaths, and 21 .1% (n = 413) of CV deaths were classified as 'other', which included ischaemic stroke, pulmonary embolism, and acute aortic syndromes, among other modes ( Table 3 ). The cumulative rates of SD, recurrent MI, heart failure, and other CV death were 0.90%, 0.67%, 0.54%, and 0.55%, respectively, at 1 year following trial enrolment for NSTE-ACS (Take home figure) . From a landmark of 30 days following the qualifying NSTE-ACS event, the cumulative incidence of SD, recurrent MI, heart failure, and other CV death at 1 year was 0.67%, 0.32%, 0.26%, and 0.28%, respectively ( Figure 2B) .
Of the 79 fatal bleeding events, 34 (43.0%) were due to intracranial haemorrhage. Malignancy accounted for 188 (33.0%) of the 569 total non-CV/non-bleeding deaths.
Relationships of modes and timing of death
Cardiovascular deaths represented the majority of deaths during both the first 30 days following randomization and after 30 days but were relatively more common during the 0-30-day period (84.5% vs. 70.0%; P < 0.001) ( Table 3) . Among CV deaths, the proportion of deaths related to recurrent MI was greater in the first 30 days than 18 .7%; P < 0.001), whereas the proportion of deaths related to SD was lower in the first 30 days (21.6% vs. 46.2%; P < 0.001). The proportion of heart failure deaths was greater before than after 30 days (24.3% to 15.7%; P < 0.001) ( Table 3 ). The cumulative incidence of SD increased steadily and more rapidly than other modes of CV death after 30 days, and by day 119 exceeded the rate of death due to recurrent MI (Take home figure) . The proportion of deaths directly related to bleeding was similarly low in the 0-30 and >30-day periods (3.4% and 2.9%, P = 0.48, respectively, of all deaths with known mode) ( Table 3) . Non-CV/nonbleeding deaths accounted for a smaller proportion of overall deaths before 30 days (12.2% in the 0-30-day period vs. 27 .1% in the >30-day period, P < 0.001). Not surprisingly, within the group of non-CV/ non-bleeding deaths, malignancy was responsible for a substantially larger proportion of these deaths beyond 30 days (40.7%) when compared with those occurring during the first 30 days (1.8%, P < 0.001).
Subgroup analyses
Patients with prior heart failure had significantly higher overall mortality rates than patients without a history of heart failure (2-year Kaplan-Meier mortality rates 15.8% vs. 5 .2%, respectively, with adjusted hazard ratio 2.2, 95% CI 2.0-2.4). The proportion of deaths related to a CV mode was higher (80.8% vs. 72.4%, excluding unknown deaths) and the proportion of deaths related to a non-CV/ non-bleeding mode was lower (17.3% vs. 24 .0%) in this group compared with those without prior heart failure (P < 0.001 for both) (see Supplementary material online, Appendix S3). The proportion of SD as a mode of CV death was similar between patients with and without prior heart failure in both the 0-30-day period (20.0% vs. 22 .8%; P = 0.44) and after day 30 (48.1% vs. 46.2%; P = 0.53).
In an analysis of deaths occurring in patients enrolled in trials with start dates prior to (n = 856) vs. after 31 December 2000 (n = 1750), the mortality rates at 1 month (1.9% vs. 1 .3%), 6 months (3.5 vs. 2.8%), and 12 months (4.8% vs. 4 .1%) were higher among the pre-2001 trials (log-rank test P = 0.028). There were no significant differences in the distribution of the general classes of death (CV, bleeding, non-CV/non-bleeding) (P = 0.87) between these two periods (see Supplementary material online, Appendix S4a). Among CV deaths, however, the proportion of SD (24.9% vs. 42.1%) was significantly lower and the proportions of deaths due to recurrent MI (30.3% vs. 20 .0%) and heart failure (24.3% vs. 16 .6%) were significantly higher among patients enrolled in trials with start dates before 31 December 2000 (P < 0.001 for each, Supplementary material online, Appendix S4a). These results were qualitatively similar even after exclusion of five trials that enrolled patients who had been stabilized post-ACS (see Supplementary material online, Appendix S4b).
Sensitivity analyses
We performed two sensitivity analyses: one restricted to the 1737 deaths with known mode occurring in the 40 667 patients enrolled with NSTEMI (i.e. excluding patients with UA), and another restricted to the 1388 deaths with known mode occurring in the 50 965 patients who survived the index hospitalization (see Supplementary material online, Appendix S5) to control for potential bias related to in-hospital monitoring. In both analyses, the differences in the proportions of each general class and specific CV mode of death between the 0-30 and >30-day periods seen in the overall cohort and described above remained significant (P < 0.001). Specifically, the proportion of CV deaths related to recurrent MI was higher and the proportion of deaths related to SD lower during the 0-30-day period compared with the >30-day period, consistent with the findings of the overall cohort. 
Discussion
In this analysis of 66 252 patients with NSTE-ACS enrolled in TIMI trials, we found that three-fourths of deaths were related to CV modes, although the relative proportion of CV deaths decreased with time following the event. Recurrent MI represented the largest proportion of CV deaths in the first 30 days following trial enrolment for NSTE-ACS, whereas SD was a proportionately greater mode of CV death after 30 days.
Outcomes following non-ST-segment elevation acute coronary syndromes
Defining the modes of death following NSTE-ACS is essential to identifying the optimal therapies and improving survival. Much of what we understand about outcomes following MI is based on studies in patients with STEMI. 11, 12 In contrast, relatively less is known about patients with NSTE-ACS, even though they are now more frequent. Only in the last decade has it been widely appreciated that patient characteristics and outcomes are different between these groups. Patients with NSTE-ACS (when compared with patients with STEMI) tend to be older, are more likely to be female, have more medical comorbidities including hypertension, diabetes, obesity, and renal dysfunction and have a greater burden of heart disease, including higher baseline rates of previous MI, heart failure, stroke, and prior revascularization. 13, 14 While short-term outcomes are worse following STEMI due to higher in-hospital mortality rates, multiple studies have shown that post-discharge mortality is actually higher among patients with NSTE-ACS, [13] [14] [15] perhaps related to older age and greater burden of these comorbidities. Regardless, the high risk of death in the mid-to longer-term following NSTE-ACS underscores the importance of understanding modes of death in this population. Deaths were grouped into one of three mutually exclusive classes-cardiovascular, bleeding, and non-CV/non-bleeding. CV deaths were subclassified into one of four specific modes-sudden death, recurrent MI, heart failure, and other CV death (includes ischaemic stroke, pulmonary embolism, acute aortic syndromes, cardiac rupture, and peripheral arterial disease). 
Sudden death following non-ST-segment elevation acute coronary syndromes
The distinct pattern of CV mortality between patients who died during the time periods of up to and beyond 30 days following trial enrolment for NSTE-ACS suggests that SD may be an important mode of late mortality in this patient group. In addition, while the absolute rate of SD was higher in patients with a history of heart failure due to the higher overall mortality rate, the comparable proportion of SD among CV deaths observed in patients with and without a history of heart failure implies that this finding may be independent of preexisting heart failure. Importantly, although SD is often attributed to an arrhythmic event, and therapies designed to prevent SD generally target ventricular tachyarrhythmia (e.g. implantable cardioverterdefibrillators), it can be difficult to distinguish whether recurrent MI is the underlying mode of SD. In addition, autopsy series of patients who died from SD often describe other modes of death (e.g. acute pulmonary embolism, aortic rupture) that were not clinically evident prior to death. 16, 17 In our analysis, the increasing proportion of SD over time was significant even when deaths occurring during the index hospitalization were excluded, suggesting that the temporal highlighted a risk of SD that extended throughout the first year following NSTE-ACS in a population generally thought to be at low risk for SD. In a pooled cohort analysis of NSTE-ACS patients enrolled in four large clinical trials, Hess et al. 23 reported that SD occurred at a rate of approximately 1% per year following NSTE-ACS and accounted for about one-third of CV deaths. Our analysis extends these findings to a larger cohort, provides additional granularity regarding other modes of CV death and demonstrates that SD is more common than other modes of CV death beyond the first month following NSTE-ACS. Our analysis also highlights the SD risk following NSTE-ACS in patients without pre-existing heart failure. The implications of our findings are several-fold. First, since the pathophysiology of SD can be variable, further investigations are needed to better define the specific causes of SD in patients who have had NSTE-ACS. For example, studies that leverage the electrocardiographic data obtained from wearable cardioverterdefibrillators or existing cardiac implantable electronic devices may offer mechanistic insights. 24 Second, it appears that while efforts to reduce re-infarction are still needed to reduce early mortality post-NSTE-ACS, interventions to reduce SD after 30 days may have a greater potential to reduce later deaths. Specific management approaches designed to modify the risk of SD in patients with NSTE-ACS merit further investigation through prospective studies. For example, closer monitoring (e.g. with implantable loop recorders) or testing (e.g. with electrophysiological studies) of patients at increased risk of SD following NSTE-ACS might identify patients who could benefit from a wearable or implantable cardioverter-defibrillator.
Fatal bleeding
Fatal bleeding was uncommon in this clinical trial population, accounting for only 3.0% of all deaths, despite the introduction of increasingly more potent antithrombotic therapies. Importantly, this may be a function of the selected populations enrolled in clinical trials and may not reflect the number of fatal bleeding events that occur in clinical practice. In addition, while bleeding may contribute to death indirectly (e.g. by resulting in interruption of important antithrombotic therapies), our analysis only accounts for fatal bleeding events, which underestimates the overall impact of bleeding.
Non-cardiovascular/non-bleeding death
Non-CV/non-bleeding deaths, especially malignancy-related deaths, accounted for a larger proportion of later deaths following NSTE-ACS in this clinical trial population. The lesser early contribution is likely related to clinical trial entry criteria, which exclude patients with active cancer and other life-threatening non-cardiac comorbid conditions. Importantly, these data highlight the increasing contribution of non-CV modes of death over time. This is especially relevant to clinical trials with long follow-up periods, which may require competing risk models to appropriately compare late survival rates between therapies.
Strengths
To our knowledge, this is the largest patient-level analysis of mortality from an NSTE-ACS clinical trial population followed long-term. Since our study population is taken exclusively from clinical trials, the fidelity of the outcomes data is generally greater than it is in large observational studies. Mortality analyses of CV disease have traditionally relied on large public registries, which often report discrepant data and lack the granularity to reliably classify CV outcomes. 25, 26 For example, many of these registries rely on ICD coding, which may not be accurate in the context of CV disease. 27 While prospective CV registries have been designed to capture outcomes following ACS, 13, 28, 29 detailed descriptions of the subcategories of CV death are generally not available, and the outcomes have not been formally adjudicated. 28 In contrast, 77% of deaths in our analysis were adjudicated by an independent CEC as part of a clinical trial, and all deaths were reviewed by two independent physician-investigators using a uniform set of prespecified criteria. In addition, our analysis includes important subgroup analyses of modes of death in patients with and without a history of heart failure and in patients enrolled prior to and after 31 December 2000, as well as valuable sensitivity analyses restricted to deaths occurring in patients with NSTEMI and deaths occurring after the index hospitalization to control for potential bias related to inhospital monitoring.
Limitations
Lack of generalizability is an often-cited limitation of using a clinical trial database since clinical trial populations are usually healthier and more likely to receive appropriate therapy. Selection bias is an especially important consideration in this mortality analysis, since patients with cancer, end-stage renal disease, severe bleeding disorders, and other life-threatening comorbidities were excluded from most of the trials. The results reported in this analysis should therefore be interpreted in that context and are not intended to provide a precise estimate of the prevalence of CV death for a general population with NSTE-ACS. Nevertheless, our study population had similar rates of prior MI, peripheral arterial disease, heart failure, and renal dysfunction when compared with cohorts derived from the Global Registry of Acute Coronary Events (GRACE). 29 The large number of CV deaths in our cohort allowed us to explore the specific CV modes of death. Our findings are most directly relevant to designing future CV trials and developing novel therapies to reduce mortality (both early and later) following NSTE-ACS.
Other limitations of our analysis deserve attention. There was variability in the duration of follow-up across the TIMI trials, so late outcomes were not available for some of the shorter and generally smaller trials, and only 25% of patients were followed for more than 17 months. In addition, there was variability between trials in the timing of trial enrolment following NSTE-ACS since some enrolled patients at the time of initial presentation and others enrolled patients who had been stabilized post-ACS. Because of the delayed timing of trial enrolment for some trials, the number of early deaths is likely to be underestimated in our cohort, and there is potential bias in the distribution of specific CV modes of death in the 0-30-day period. Nevertheless, the median time from onset of the index event to study enrolment was 1 day for the merged cohort. Furthermore, the landmark analyses of general class and specific CV mode of death
starting at 30 days following the qualifying NSTE-ACS event closely parallel the results of the primary analysis.
Finally, accurately classifying mode of death is complicated for many reasons. First, mode of death is often multifactorial, especially for patients with NSTE-ACS who are elderly and often have multiple comorbidities. Second, assigning mode of death to a single (or the most proximate) event may not adequately describe the clinical nuances involved in a patient's death. For example, bleeding may prompt a healthcare provider to discontinue antithrombotic or other therapies, thereby increasing the risk of recurrent ischaemic events. 30 Third, CV death classifications often have overlapping pathophysiologies and may not fit cleanly into one category, as in the case of SD. To this end, there have been efforts to standardize definitions for endpoint events in CV trials and to provide greater granularity regarding potential causal relationships that may be implicated in a patient's death, 5 which are important but remain imperfect. These challenges in analysing mortality data are not unique to the present analysis, and highlight the importance of using validated methods to assess modes of death (e.g. postmortem examination).
Conclusion
Cardiovascular events are responsible for the majority of deaths following NSTE-ACS in a population derived from CV clinical trials over a 25-year period. Modifying CV risk following NSTE-ACS is paramount to improving survival in this population. Recurrent MI represents the largest proportion of CV deaths in the first 30 days following NSTE-ACS, whereas SD is a proportionately greater mode of death beyond 30 days in a CV clinical trial population. Further investigations aimed at defining the epidemiology of SD and developing specific therapies and management approaches to reduce SD following NSTE-ACS may be critical to reducing late mortality.
Supplementary material
Supplementary material is available at European Heart Journal online. We present the case of a medium age male patient with acute myocardial infarction and secondary ventricular septal defect (VSD). He underwent emergency surgery to repair of post-infarction VSD by David infarct exclusion technique.
A pericardial patch was attached to the endocardium of the left ventricle (LV) all around the necrotic myocardium to exclude the VSD and the infarct from the left ventricular cavity.
A week after the procedure, the patient clinical condition was good but there was a typical murmur of a VSD. By Doppler ultrasound a small flow with apparently no communication with the LV was assessed through the VSD.
A cardiac MRI was performed, with a protocol that included 4D flow sequence (a tridimensional flow sequence with temporal resolution).
In the anatomic sequences, the pericardial patch showed no defect. Because of the technique of David exclusion, the right ventricle (RV) remained communicated through the VSD with a thin false cavity between the residual interventricular septum and the pericardial patch. Fourdimensional flow images showed a small defect between the left ventricular apex and the pericardial patch. Through this defect, there was a small flow from LV passing towards the previously described false cavity between pericardial patch and residual septum. This flow presented posterior and superior direction to finally communicate with the RV through the VSD. Besides direct visualization of the flow, with 4D flow sequence we could measure the shunt flow (4 L/min) and obtain indirect sign of leftright shunt (Qp/Qs ratio: 3:2). As the ventricular function and the clinical evolution of the patient were good and there were no symptoms of left ventricular overload, follow-up was decided, monitoring with US and MRI. Doppler ultrasound 6 months after showed no changes.
Four-dimensional flow imaging where colour depends on velocity magnitude and vectors show flow direction. Panel A shows coronal MIP reconstruction. Panel B shows four chambers image. Panel C shows oblique short-axis image.Small flow through small defect in the LV apex between LV and the pericardial patch (arrow in Panel C) goes towards the false thin cavity (asterisk) between pericardial path and residual interventricular septum. It is shown the shunt between the false cavity and the RV (left-right shunt) through VSD (arrows in Panels A and B).
Supplementary material is available at European Heart Journal online.
